Millennium Management’s RAPT Therapeutics RAPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-18,750
Closed -$458K 6405
2024
Q2
$458K Buy
18,750
+15,000
+400% +$693K ﹤0.01% 4644
2024
Q1
$269K Buy
3,750
+1,250
+50% +$174K ﹤0.01% 5202
2023
Q4
$497K Hold
2,500
﹤0.01% 4646
2023
Q3
$332K Buy
+2,500
New +$408K ﹤0.01% 4877
2023
Q2
Sell
-2,500
Closed -$367K 6588
2023
Q1
$367K Buy
+2,500
New +$506K ﹤0.01% 4785
2022
Q4
Sell
-6,250
Closed -$1.2M 6950
2022
Q3
$1.2M Buy
+6,250
New +$1.18M ﹤0.01% 4179
2021
Q4
Sell
-5,000
Closed -$1.24M 7278
2021
Q3
$1.24M Buy
+5,000
New +$1.32M ﹤0.01% 4448
2021
Q1
Sell
-1,250
Closed -$198K 6417
2020
Q4
$198K Sell
1,250
-1,275
-50% -$277K ﹤0.01% 4814
2020
Q3
$650 Buy
+2,525
New +$560K ﹤0.01% 3437

Millennium Management's RAPT Position: Q1 2026 in Review

Millennium Management sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 106,671 shares — an estimated $3.61M sold.

Millennium Management first reported a position in RAPT in Q1 2020 and held it in 24 quarters. The position peaked at $15.4M in Q3 2021. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.

  • Millennium Management reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Millennium Management sold 106,671 RAPT Therapeutics shares in Q1 2026, an estimated $3.61M.
  • Millennium Management first reported a position in RAPT Therapeutics in Q1 2020 and held it in 24 quarters.
  • Millennium Management's RAPT Therapeutics position peaked at $15.4M in Q3 2021.
  • 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.